Home Alzheimer’s Disease Phase II Trial of Leronlimab for COVID-19 Enrolls First Patients

Phase II Trial of Leronlimab for COVID-19 Enrolls First Patients

CytoDyn announced that it has enrolled and treated the first 2 patients with coronavirus disease 2019 (COVID-19) with leronlimab (PRO 140) – a treatment in the pipeline as a treatment for patients with triple-negative breast cancer (TNBC) – under its phase II randomized clinical trial, which is specifically for those with mild-to-moderate indications.1

The phase II clinical trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of leronlimab and calls for 75 planned patients in up to 10 centers in the US.2

Additionally, leronlimab has now been administered to 15 severely ill patients with COVID-19 at 4 hospitals, with 10 patients being treated at a leading medical center in the New York City area and 5 patients at 3 other hospitals. The patients were all able to be administered the agent under an emergency investigational new drug (EIND),…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Conducting a survey research, regarding Genetic tests for cancer. : braincancer

I am a Service Design Student at the Royal College of Art, London. I am working with the NHS Genomics, the scope of the...

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

Recent Comments